Stryker Co. (NYSE:SYK) Shares Acquired by Deutsche Bank AG

Deutsche Bank AG increased its stake in Stryker Co. (NYSE:SYK - Free Report) by 8.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 863,878 shares of the medical technology company's stock after purchasing an additional 63,909 shares during the period. Deutsche Bank AG owned 0.23% of Stryker worth $311,039,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of SYK. Norges Bank acquired a new stake in shares of Stryker during the fourth quarter worth about $1,710,744,000. Raymond James Financial Inc. acquired a new stake in shares of Stryker during the fourth quarter worth about $353,394,000. FMR LLC lifted its holdings in shares of Stryker by 10.0% during the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock worth $2,892,946,000 after purchasing an additional 727,850 shares during the period. Proficio Capital Partners LLC lifted its holdings in shares of Stryker by 52,520.8% during the fourth quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company's stock worth $214,660,000 after purchasing an additional 595,061 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of Stryker by 13.2% during the fourth quarter. Northern Trust Corp now owns 3,606,237 shares of the medical technology company's stock worth $1,298,426,000 after purchasing an additional 420,153 shares during the period. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Trading Down 0.4%

Shares of SYK traded down $1.59 during midday trading on Friday, hitting $380.87. 758,784 shares of the stock were exchanged, compared to its average volume of 1,356,009. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The stock has a fifty day simple moving average of $365.47 and a 200 day simple moving average of $374.48. The firm has a market cap of $145.37 billion, a P/E ratio of 49.08, a P/E/G ratio of 2.93 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. During the same quarter in the prior year, the company earned $2.50 EPS. Stryker's revenue was up 11.9% on a year-over-year basis. On average, research analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date is Monday, June 30th. Stryker's dividend payout ratio (DPR) is currently 45.41%.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the transaction, the director now owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares of the company's stock, valued at $5,705,827.65. This trade represents a 14.16% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Wall Street Analyst Weigh In

SYK has been the topic of several recent research reports. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Roth Mkm lifted their target price on shares of Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. StockNews.com cut shares of Stryker from a "buy" rating to a "hold" rating in a research note on Thursday, March 6th. Argus set a $450.00 target price on Stryker in a report on Monday, February 3rd. Finally, Barclays upped their target price on Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $427.05.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.